Yale-launched bioscience/tech firm, backed by Connecticut Innovations and CTNext, quadruples employee base since 2017
Founded by a handful of Yale faculty and researchers, Isoplexis has quickly become recognized worldwide for its technology providing quicker, more accurate diagnosis and evaluation of treatment options for people with cancer and other diseases. In 2021 it was named one of the “Fierce 15,” a national trade publication’s list of 15 biotechnologies with the greatest potential to impact healthcare quality.
In 2017, the Branford-based company had 40 employees; today, it has more than 250, 150 in Connecticut. The average salary is over $121,000, reflecting a trend in the state of a growing number of bioscience companies (now more than 1,000) paying a much higher than average wage. Isoplexis has received significant investment and support from Connecticut Innovations, including $7.5 million in total investment ($1.1 million in CBIF investment). CI has also assisted the company in other ways, providing help with finding lab facilities and identifying new executive staff. CTNext supported Isoplexis’s talent search through its Technology Talent Bridge program and provided SBIR training and counsel.
For more information about Isoplexis Corp., visit www.isoplexis.com.